Patents Assigned to ALECTOR LLC
-
Publication number: 20200317776Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: March 30, 2020Publication date: October 8, 2020Applicant: Alector LLCInventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
-
Publication number: 20200277374Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 14, 2020Publication date: September 3, 2020Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
-
Publication number: 20200223928Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 13, 2020Publication date: July 16, 2020Applicant: Alector LLCInventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS
-
Patent number: 10711062Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: July 14, 2020Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
-
Patent number: 10676525Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: June 9, 2020Assignee: ALECTOR LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Publication number: 20200131264Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: March 3, 2017Publication date: April 30, 2020Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
-
Patent number: 10590198Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 26, 2016Date of Patent: March 17, 2020Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
-
Publication number: 20200024348Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: July 12, 2019Publication date: January 23, 2020Applicant: Alector LLCInventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
-
Publication number: 20190367588Abstract: The present disclosure generally relates to antigen-binding proteins (ABPs) that specifically bind to apolipoprotein E (ApoE), compositions comprising such ABPs, methods of using such ABPs, and methods of making such ABPs. In some embodiments, the ABPs provided herein bind lipidated ApoE4. In some embodiments, the lipidated ApoE4 is within a lipoprotein particle, and the ABPs therefore bind to a lipoprotein particle comprising ApoE4. Any suitable ABP may be used. In some embodiments, the ABP is an antibody. In some embodiments, the ABP is an alternative scaffold. The ABPs provided herein may be used for the prevention or treatment of any disease, condition or disorder associated with ApoE4 expression.Type: ApplicationFiled: January 10, 2019Publication date: December 5, 2019Applicant: Alector LLCInventor: Arnon Rosenthal
-
Publication number: 20190359707Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Publication number: 20190330335Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: October 6, 2016Publication date: October 31, 2019Applicant: ALECTOR LLCInventors: Tina SCHWABE, Francesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
-
Publication number: 20190315858Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 11, 2019Publication date: October 17, 2019Applicant: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Patent number: 10428150Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 20, 2018Date of Patent: October 1, 2019Assignee: Alector LLCInventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
-
Publication number: 20190275150Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: ApplicationFiled: December 8, 2017Publication date: September 12, 2019Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
-
Publication number: 20190233496Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent a neurological disease, disorder, or injury.Type: ApplicationFiled: September 4, 2018Publication date: August 1, 2019Applicant: Alector LLCInventor: Arnon ROSENTHAL
-
Publication number: 20190174730Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.Type: ApplicationFiled: December 12, 2018Publication date: June 13, 2019Applicant: Alector LLCInventors: Ilaria Tassi, Asa Abeliovich, Seung-Joo Lee, Arnon Rosenthal, Tina Schwabe
-
Patent number: 10308718Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: January 10, 2018Date of Patent: June 4, 2019Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
-
Publication number: 20190127475Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 20, 2018Publication date: May 2, 2019Applicant: Alector LLCInventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS
-
Publication number: 20190085076Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 11, 2016Publication date: March 21, 2019Applicant: ALECTOR LLCInventors: Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
-
Publication number: 20190085084Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: September 18, 2018Publication date: March 21, 2019Applicant: Alector LLCInventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas